NFI Group

Stock factsheet

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. We do not have a verified market capitalisation for this company.

Company profile

Comparable companies

Companies in the Industrials & Manufacturing sector of a similar size.

News timeline

1. 01.11.2026 FDA Approval as a Turning Point: What Inovio's VOCERYQ Teaches Biotech Investors
2. 01.11.2026 Burn Rate, Concentration Risk, Regulation: What IPO Risks Teach AI Small-Cap Investors
3. 31.10.2026 From Silicon Sample to Volume Order: Design Wins in the Semiconductor Market
4. 30.10.2026 Patriot Suppliers: How Major Contracts Reshape the Supply Chain
5. 30.10.2026 AI in Orbit: What On-Board Inference Means for Space-Tech Investors
6. 29.10.2026 Open-Weight AI: What Open Models Mean for Cybersecurity Niches
7. 28.10.2026 Green Ammonia: How Derivatives Unlock Hydrogen Exports
8. 28.10.2026 Strategic Partnership or Golden Cage? What Big-Tech Entry Means for the Quantum Market
9. 27.10.2026 RED IV and FIDs: Why Regulatory Risk Is Stalling Green Hydrogen Projects
10. 27.10.2026 China's Satellite Tripling: What It Means for Western Space Small Caps
11. 27.10.2026 Drone Defence Architecture: What Book-to-Bill Reveals for Small Caps
12. 26.10.2026 Government Contract or Revenue Guarantee? Quantum Small Caps Examined
13. 24.10.2026 China Biotech Restrictions: What Licence Exemptions Mean for Cross-Border Deals
14. 24.10.2026 AI Ad Labelling: What Regulation Means for Ad-Tech Small Caps
15. 23.10.2026 Healthcare Data Breaches: What They Mean for Cybersecurity Niche Providers
16. 21.10.2026 Satellite QKD: How Quantum Cryptography From Space Works
17. 21.10.2026 EV/ARR Multiples Explained: What Niche AI Valuations Really Reveal
18. 21.10.2026 Self-Optimising AI: What Automated Model Training Means for Small-Cap Developers
19. 20.10.2026 Platform Consolidation in Life-Science AI: Who Will Survive?
20. 19.10.2026 Spectrum Race in Space: What LOIs Mean for Satellite Small Caps
21. 19.10.2026 Autonomous AI Attacks: What Agent-Based Hacks Mean for Cybersecurity Stocks
22. 19.10.2026 Tenstorrent & RISC-V: What Open Chip Architecture Really Promises
23. 18.10.2026 Modular Home Battery Storage: Price Pressure and Opportunities for CleanTech Suppliers
24. 18.10.2026 Analyst Ratings & Shareholder Structure: Lessons for Small-Cap Investors
25. 17.10.2026 Google's Quantum Milestone: What Error Rate Reduction Really Means
26. 17.10.2026 When Giants Acquire: What Defence Takeovers Mean for Small-Cap Investors
27. 16.10.2026 AdFection Spyware: How Surveillance Scandals Move the Cybersecurity Market
28. 15.10.2026 First Paying Pharma Customer: What It Means for Quantum Start-ups
29. 15.10.2026 Pure Plays vs. Enablers: Who Survives in the Quantum Market?
30. 14.10.2026 Understanding Dilution: What Pre-Funded Warrants Cost Biotech Investors
31. 13.10.2026 Drone Defence Components: How Suppliers Profit from the C-UAS Market
32. 13.10.2026 Satellite Platforms: What Open Orbital Software Really Delivers
33. 12.10.2026 Radiopharmaceuticals in Phase 3: What BMS' RayzeBio Deal Teaches Us
34. 12.10.2026 Hyperscaler In-House AI Chips: What Custom Silicon Means for the Semiconductor Market
35. 11.10.2026 Rising Bond Yields & Small-Cap Valuations: What Investors Must Know
36. 09.10.2026 Commercial PNT: What GPS Alternatives Reveal About Space Small Caps
37. 09.10.2026 Failed IPO: What Cancelled Listings Reveal About AI Valuations
38. 06.10.2026 Orbital Slots & Spectrum Scarcity: What the Satellite Rush Really Costs
39. 06.10.2026 From Pilot Programme to Serial Contract: Directed Energy as Drone Defence
40. 04.10.2026 Camera vs. Lidar: Cost Curves Decide the Sensor Race in Autonomous Driving
41. 29.09.2026 Reading IPO Prospectuses: What Risk Factors Reveal About AI Valuations
42. 28.09.2026 Qualification Barriers: What Access Hurdles Mean for Defense Small Caps
43. 27.09.2026 Autonomous Naval Vessels: What MUSV Procurement Really Means
44. 27.09.2026 Cash Runway, Burn Rate & Technology: Three Benchmarks for Quantum Pure-Plays
45. 26.09.2026 Convertible Notes as Growth Capital: What Nscale's $3.4B Round Reveals
46. 25.09.2026 IonQ and Nvidia: When Qubit Milestones Meet Stock Prices
47. 21.09.2026 Analyst Ratings in Quantum Stocks: What Valuations Really Measure
48. 20.09.2026 When AI Systems Break Out: Security Vulnerabilities and Market Implications
49. 19.09.2026 China's $500 Billion Biotech Plan: Why IP Strategy Is What Really Counts
50. 17.09.2026 Serial Production Over Innovation: The New Procurement Logic in Counter-UAS
51. 15.09.2026 Space Unicorns vs. Listed Small Caps: A Valuation Comparison
52. 15.09.2026 Engine License vs. Acquisition: What Vertical Integration Costs Defense Small Caps
53. 15.09.2026 Anthropic's Nasdaq IPO: What a Mega-Listing Means for AI Small Caps
54. 14.09.2026 Oil Price Shock as a Catalyst: What Cleantech Investors Must Really Check
55. 14.09.2026 AI Regulation: What Policy Frameworks Mean for Small-Cap Investors
56. 13.09.2026 Make-or-Buy in the Lab: AI Orchestration and Its Impact on Biotech Investors
57. 13.09.2026 OpenAI Stays Private: Liquidity Pressure on Listed AI Small Caps
58. 12.09.2026 National Hydrogen Quotas Phased Out: What EU-Wide Targets Mean for Project Finance
59. 12.09.2026 Board Appointments as IPO Signal: What AI Cloud Listings Really Need
60. 11.09.2026 Series F at $275M: What Orphan Gene Therapy Really Costs
61. 11.09.2026 Qualified Vendor Status: How Drone Procurement Selects Suppliers
62. 11.09.2026 Biotech Diversionary Pivots: Opportunity or Red Flag?
63. 09.09.2026 Decentralized Defense Production: What MBDA in Poland Means for Suppliers
64. 09.09.2026 FAA Certification as the Key: What Autonomous Cargo Aircraft Really Cost
65. 09.09.2026 Government Stakes in Quantum Computing: What $100M Deals Really Mean
66. 08.09.2026 mRNA Platform Logic: What Licensing and In-House Manufacturing Mean for Small Caps
67. 08.09.2026 Bankruptcy Before FDA Decision: When the Cash Runway Runs Out
68. 07.09.2026 First Launch & What Comes Next: How to Assess Orbital Small Caps
69. 06.09.2026 Niche Moats in Government Cybersecurity: What Investors Need to Know
70. 06.09.2026 After FDA Approval: When the Price Surge Raises New Questions
71. 05.09.2026 KDDX Destroyer: How Naval Turbine Contracts Move Defense Supplier Small Caps
72. 03.09.2026 Copyright Meets AI Training: What the U.S. Position Means for Data Providers
73. 02.09.2026 Reverse Merger vs. IPO: Three Paths to Market for Biotech Investors
74. 01.09.2026 Vertical Integration: When UAV Small Caps Acquire Their Suppliers
75. 31.08.2026 Import Barriers on Drones: How Trade Policy Is Splitting Supply Chains
76. 28.08.2026 Government Ransomware Attacks: How Federal Incidents Reshape the Cybersecurity Market
77. 27.08.2026 Radiation-Hardened Chips: Why On-Board Computers in Orbit Are Becoming Scarce
78. 27.08.2026 Pentagon Supply Chains: What Defense Framework Agreements Really Mean
79. 27.08.2026 Medical Technology Under Attack: What OT Security Means for Niche Providers
80. 26.08.2026 510(k) Pathway for AI Medical Devices: What an ECG Clearance Really Proves
81. 25.08.2026 Executive Orders & Quantum Stocks: What Political Tailwinds Actually Deliver
82. 25.08.2026 From Prototype to Series Contract: Defense Small Caps and Long Cycles
83. 25.08.2026 Pentagon Shoot-Offs: How Defense Small Caps Must Prove Themselves in Live Competition
84. 24.08.2026 Design Wins vs. AI Hype: What Really Sets Fabless Small Caps Apart
85. 22.08.2026 Gene Therapy Approvals: How Safety Incidents Reshape the Entire Sector
86. 22.08.2026 Q2 Quantum Computing Earnings: Real Turning Point or Just a Rally?
87. 21.08.2026 NSSTS Strategy Document: Which Technologies Enjoy Pentagon Priority
88. 21.08.2026 OpenAI IPO: How a Mega-IPO Is Reshaping the AI Ecosystem
89. 20.08.2026 Billion-Dollar Hypersonic Funding: What Castelion's Round Teaches Investors
90. 19.08.2026 AI Safety Infrastructure: What Sandbox Failures Mean for Investors
91. 18.08.2026 PLA Doctrine Shifts: What It Means for NATO Defense Small Caps
92. 18.08.2026 Neocloud Pivot: What Groq's Strategy Shift Reveals About AI Infrastructure
93. 15.08.2026 Military Energy Gap: How Drone Fleets Are Overwhelming Power Supply
94. 11.08.2026 Event Windows in Space Stocks: Volatility Without a Change in Value
95. 11.08.2026 Narrative vs. Fundamentals: What QUBT Investors Underestimate
96. 11.08.2026 IBM's Quantum Horizon: What a Tech Giant's Timeline Means for Pure-Play Providers
97. 11.08.2026 Licensing Deal or Acquisition? How Strong Trial Data Shift Biotech Power Dynamics
98. 11.08.2026 When Big Tech Sets the Direction: Niches for Small-Cap Investors
99. 11.08.2026 Optical Laser Links in Space: From Demo to Business Model
100. 11.08.2026 IDIQ Contracts & Loitering Munition: What Drone Orders Really Mean
101. 11.08.2026 Dosing Interval in Phase 2: What Biotech Investors Really Need to Check
102. 11.08.2026 Foundation Models in Cybersecurity: Who Wins the AI Defense Race?
103. 09.08.2026 AI Agents Out of Control: Containment as a New Competitive Differentiator
104. 09.08.2026 Biotech IPOs: What an IPO Window Means for Small-Cap Investors
105. 09.08.2026 When AI Becomes a Cyberweapon: What Security Thresholds Mean
106. 07.08.2026 EU Subsidies for Hydrogen: Opportunity and Dependency at Once
107. 07.08.2026 IRIS² Mega-Program: How Framework Agreements Move Small-Cap Suppliers
108. 07.08.2026 Rising Revenue, Falling Stock: What the Rigetti Paradox Teaches Investors
109. 07.08.2026 Design-Win to Volume Order: How Fabless Chip Designers Work
110. 07.08.2026 Counter-Drone Procurement: When Price Rewrites the Rules of Competition
111. 07.08.2026 Composite Endpoints: When Trial Data Can Be Misleading
112. 06.08.2026 Cybersecurity IPO on the ASX: What Investors Need to Know About Stock Exchanges
113. 06.08.2026 Reading Clinical Biotech Q2 Reports: How to Decode the Catalyst Calendar
114. 06.08.2026 SAR Satellite Contracts: How the NRO Evaluates Small Space Companies
115. 06.08.2026 AI Monetization in Small Caps: ARR, Margins, and Real Contracts
116. 05.08.2026 Quantum Computing Stocks: How to Read Burn Rate Before Q2 Earnings
117. 05.08.2026 AI Regulation: What the U.S. Testing Framework Means for Open Models
118. 05.08.2026 When Infrastructure Becomes an AI Business Model: What Investors Need to Know
119. 05.08.2026 Government Contracts as Growth Engines: What Defense Orders Mean for Space Small Caps
120. 05.08.2026 Biotech M&A: When Small Caps Become Acquisition Targets
121. 05.08.2026 Hughes Bankruptcy: What LEO Disruption Means for Satellite Investors
122. 05.08.2026 Satellite Propulsion for Defense: How Small Caps Benefit from the Defense Boom
123. 05.08.2026 Quantum Small Caps: When Tech Milestones Don't Equal Revenue
124. 05.08.2026 When a Space Company Becomes a Data Center Operator: Lessons for Small-Cap Investors
125. 05.08.2026 Defense Contracts as a Revenue Base for Satellite Small Caps
126. 04.08.2026 Rocketdyne Spinout: What PE-Driven Carve-Outs Mean for the Space Sector
127. 04.08.2026 Satellite Propulsion: How Military Demand Shapes a Small-Cap Niche
128. 03.08.2026 Government Satellite Contracts: What Demo Deals Mean for Space Small Caps
129. 03.08.2026 AI Security Validation: What Valuation Jumps Really Mean
130. 03.08.2026 IND Process & FDA Trialblazer: What Changes for Biotech Small Caps
131. 03.08.2026 Defense Contracts in Space: Large Corp vs. Start-Up — What Investors Should Know
132. 03.08.2026 Continuous Validation: How AI Is Reshaping the Cybersecurity Market
133. 03.08.2026 Laser Communication in Orbit: What Demonstration Contracts Mean for Space Small Caps
134. 03.08.2026 AI-Powered Security Validation: Continuous Monitoring Replaces the Annual Pentest
135. 03.08.2026 Demonstration Contracts in Orbit: What Navy Awards Mean for Space Start-Ups
136. 03.08.2026 Revenue Guidance Upgrade After Approval: What It Means for Biotech Investors
137. 03.08.2026 Pivotal Trials in Oncology: What Phase 2/3 Data Really Mean
138. 02.08.2026 AI Copyright: When Training Data Becomes a Liability Risk
139. 01.08.2026 Laser Communication in Orbit: What Military Contracts Mean for Space Small Caps
140. 31.07.2026 SRAM in the AI Era: How Niche Chips Promise Data Center Returns
141. 30.07.2026 Defense IPO Postponed: What Really Drives Valuation Expectations
142. 29.07.2026 Defense IPO Timing: Why Strong Order Backlogs Aren't Enough
143. 28.07.2026 GLP-1 for Addiction: What Phase II Trial Data Really Promise
144. 27.07.2026 FDA Reviewers vs. Sponsor: When Regulators and Biotech Read Data Differently
145. 24.07.2026 Quantum Correction: Valuation Reset or Fundamental Breakdown?
146. 23.07.2026 Megacap Acquisitions in the Quantum Market: Opportunity or Displacement?
147. 22.07.2026 Framework Agreement or Firm Order? How Small-Cap Investors Read AI Deals
148. 20.07.2026 Dilution in Quantum Small Caps: How to Read a Capital Increase
149. 17.07.2026 Pump-and-Dump: How Regulation Dried Up Micro-Cap IPOs
150. 16.07.2026 Russell 2000 at Record High: Macro Signals for Small-Cap Investors
151. 15.07.2026 AI Platform Pressure: How Cybersecurity Small Caps Defend Their Niche
152. 13.07.2026 Micro-Cap Biotech: What Really Drives Share Price Losses
153. 09.07.2026 Hong Kong IPO Market: When Megadeals Crowd Out Small-Cap Listings
154. 08.07.2026 AI Infrastructure Small Caps: ARR, Margins, and Concentration Risk
155. 30.07.2026 Quantum Computing Stocks: When One Contract Moves the Market
156. 30.07.2026 FDA Adcom: What a Negative Vote Costs Biotech Investors
157. — Biotech IPOs 2026: What an Open IPO Window Really Means

Investor Relations

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.